Friday, February 16, 2024 1:37:55 PM
Name Research Code Research Phase Company Indications Clinical Trials
Lorvotuzumab mertansine BB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1 Phase 2 Clinical Immunogen Inc Ovarian Neoplasms; Leukemia; Rhabdomyosarcoma; Carcinoma, Merkel Cell; Small Cell Lung Carcinoma; Wilms Tumor; Multiple Myeloma; Sarcoma, Synovial; Neurofibrosarcoma; Neuroblastoma; Carcinoma, Small Cell
Details
GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR GD2/CD56 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms
Details
CUBT-906 CUBT-906 Phase 2 Clinical Curative Biotechnology Inc
Recent CUBT News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/06/2024 09:31:41 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM